Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

CHANTIX® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX

Business Wire January 24, 2013

Pfizer Partnership Organizations Significantly Benefit From Pfizer's Global Health Fellows Program

Business Wire January 22, 2013

Pfizer's Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe

Business Wire January 18, 2013

Data Shows Peak Cold and Flu Season is Here for Chicago

Business Wire January 16, 2013

Top Pharmaceutical Stocks for 2013: Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc., and Eli Lilly and Company

PR Newswire January 16, 2013

Data Shows Peak Cold and Flu Season is Here for Philadelphia

Business Wire January 16, 2013

Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects

PR Newswire January 16, 2013

Pfizer Announces Availability Of Quillivant XR(tm) (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States

Business Wire January 14, 2013

Perfect Trade Setups, How to Play BSX, NBY, BTX and PFE

Marketwired January 9, 2013

Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease

Business Wire January 8, 2013

The Real Story Behind ABT, HLF, PFE and GSK

Marketwired January 4, 2013

Most Active Stocks as The Market Starts The New Year Off on a Bull run!

PR Newswire January 3, 2013

S&P 500 Index Gains the Most Since 2009 -- Fiscal Cliff Likely to Be Avoided

Marketwired January 3, 2013

U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Business Wire January 2, 2013

Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)

Business Wire December 28, 2012

Friday's Most Active - SPY, PFE, MS and FITB

Marketwired December 28, 2012

Perfect Trade Setups, How to Play S, PFE, GE and INTC

Marketwired December 28, 2012

ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation

Business Wire December 26, 2012

Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase

PR Newswire December 21, 2012

Humedica and Pfizer Form Strategic Alliance

Business Wire December 20, 2012